SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Ionis Pharmaceuticals (IONS)
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
4676 121 0 IONS
Emcee:  Keith Fauci Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3176Isis Pharmaceuticals Receives Key Antisense Technology Patent - New Patent StrenSemiBull-12/12/2001
3175ON24: ISIS-2302 enters phase III trials biz.yahoo.comSemiBull-12/3/2001
3174Tuck, Thanks for the insight. As I seem to recall, there was some chatter on SemiBull-11/29/2001
3173SB, Well, they're not saying a lot. They're using complete clinical retuck-11/29/2001
3172Hey Tuck, Do you perceive any differences in this study of 2302 for Chrohn'SemiBull-11/29/2001
3171Well, here we go again . . . >>CARLSBAD, Calif., Nov. 29 /PRNewswiretuck-11/29/2001
3170ON24: Phase II clinical investigation of ISIS-104838 biz.yahoo.comSemiBull-11/26/2001
3169OncoGenex Technologies and Isis Pharmaceuticals To Develop Antisense Drug for PrSemiBull-11/26/2001
3168Isis Pharmaceuticals Initiates Phase II Clinical Trial of Isis 104838, A TNF-AlpSemiBull-11/19/2001
3167CAMBRIDGE, Mass., Nov. 15 /PRNewswire/ -- Hybridon, Inc. (OTC Bulletin Board: HYnigel bates-11/15/2001
3166Mike King initiates coverage with $32 price target. King is the best on the StreElmer-11/8/2001
3165Jim McCamant recommends ISIP (again) in the current issue of Worth. What is inteElmer-11/2/2001
3164Mike King on Biotech outlook netroadshow.comElmer-10/31/2001
3163Isis Pharmaceuticals Announces Exercise of Over-Allotment Option In Public OfferSemiBull-10/30/2001
3162ISIS 3521 Maintains Favorable Prolonged Survival and Strong Overall Response RatSemiBull-10/30/2001
3161ON24 Spotlight: Isis Pharmaceuticals biz.yahoo.comSemiBull-10/29/2001
3160Just wanted to say thanks for keeping us up to date. mjMJ-10/25/2001
3159Isis Pharmaceuticals Announces Successful Completion Of Public Offering biz.yahoSemiBull-10/25/2001
3158Really nice price action considering that they just increased the float 10%.Elmer-10/23/2001
3157Isis Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering biz.yahoo.comSemiBull-10/23/2001
3156Isis Pharmaceuticals Reports Third Quarter 2001 Highlights and Financial ResultsSemiBull-10/17/2001
3155ISIS - 2302 generates positive phase II data [audio 1.1 min] biz.yahoo.comSemiBull-10/15/2001
3154How the worm turns.... Phase II Study of Antisense Drug ISIS 2302 Demonstrates SemiBull-10/10/2001
3153More good news from ISIP this morning on UC drug.Arthur Radley-10/10/2001
3152Isis Pharmaceuticals to sell 5 mln shares biz.yahoo.comSemiBull-10/9/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News